Get exclusive money-saving offers and guides
Straight to your inbox
By signing up, you agree to the Finder
Privacy & Cookies Policy
and
Terms of Use, Disclaimer & Privacy Policy.
How to buy Pharmaxis shares
Own Pharmaxis shares in just a few minutes.
Updated
Fact checked
Investments
We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Pharmaxis Ltd is a drug manufacturers—general business based in Australia. Pharmaxis shares (PXS) are listed on the Australian Securities Exchange (ASX) and all prices are listed in Australian Dollars. Pharmaxis has a trailing 12-month revenue of around $12.6 million..
How to buy shares in Pharmaxis
- Compare share trading platforms. To buy shares listed in Australia, you'll need to sign up to a broker with access to the Australian Securities Exchange (ASX). Our table below can help you choose.
- Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, PayPal or debit card.
- Search for Pharmaxis . Find the share by name or ticker symbol: PXS. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Pharmaxis reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. At today's price of $0.094, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs.
- Check in on your investment. Congratulations, you own a part of Pharmaxis . Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
Our top pick for
US stocks
Finder Award
Our top pick for
Cheap broker fees
Finder Award
Our top pick for
Long-term investing
Finder Award
🧪How we chose these brokers
For our Top Picks, we compared our Finder partners using a proprietary algorithm in August 2020. Keep in mind that our top picks may not always be the best for you, and you're encouraged to compare for yourself to find one that works for you. Read our full methodology here to find out more.Pharmaxis share price
Use our graph to track the performance of PXS stocks over time.Pharmaxis shares at a glance
Information last updated 2020-10-20.
| 52-week range | $0.053 - $0.285 |
|---|---|
| 50-day moving average | $0.0861 |
| 200-day moving average | $0.0878 |
| Target price | $0.52 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-0.053 |
Share Trading Account Offer
IG Share Trading Offer
AUD 8
Standard brokerage - Australian shares
Share Trading Account Offer
Competitive broker fees on Australian and international shares
- Brokerage - AU shares: From AUD 5 or 0.05%
- Brokerage - US shares: USD 0
- Sign-up process: Instant
- Support - After hours: Yes
More info
Important: Share trading carries risk of capital loss.
Compare share trading platforms
The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.
Is it a good time to buy Pharmaxis stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Pharmaxis price performance over time
Historical closes compared with the close of A$0.094 on 2020-10-22
| 1 week (2021-01-15) | -4.08% |
|---|---|
| 1 month (2020-12-23) | 11.90% |
| 3 months (2020-10-23) | 6.82% |
| 6 months (2020-07-23) | 11.90% |
| 1 year (2020-01-23) | -24.80% |
|---|---|
| 2 years (2019-01-23) | -64.53% |
| 3 years (2018-01-23) | -63.85% |
| 5 years (2016-01-22) | -71.08% |
Pharmaxis financials
| Revenue TTM | $12.6 million |
|---|---|
| Gross profit TTM | $11.2 million |
| Return on assets TTM | -22.53% |
| Return on equity TTM | -171.66% |
| Profit margin | -110.53% |
| Book value | 0.004 |
| Market capitalisation | $36 million |
TTM: trailing 12 months
Pharmaxis share dividends
We're not expecting Pharmaxis to pay a dividend over the next 12 months.
Pharmaxis share price volatility
Over the last 12 months, Pharmaxis 's shares have ranged in value from as little as $0.053 up to $0.285. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (AU average) beta is 1, while Pharmaxis 's is 0.508. This would suggest that Pharmaxis 's shares are less volatile than average (for this exchange).
Pharmaxis overview
Pharmaxis Ltd engages in the research, development, and commercialization of healthcare products for the treatment of fibrotic and inflammatory diseases worldwide. The company operates through two segments, Mannitol business, and New Drug Development. It offers Bronchitol, an inhaled dry powder for the treatment of cystic fibrosis; and Aridol, an airways inflammation test that is used to identify twitchy or hyper-responsive airways, as well as to assist in diagnosing and managing asthma. The company's product pipeline consists of amine oxidase inhibitors comprising semicarbazide-sensitive amine oxidase for diabetic retinopathy; selective lysyl oxidase like inhibitors targeting chronic fibrotic diseases, such as NASH, pulmonary fibrosis, kidney fibrosis, and cardiac fibrosis; and pan-lysyl oxidase inhibitors targeting severe fibrotic indications, which includes cancers and scarring. It is also developing Orbital, a dry powder inhaler to deliver high drug doses to lungs. Pharmaxis Ltd was founded in 1998 and is headquartered in Frenchs Forest, Australia.
Frequently asked questions
Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs comes with a higher risk of losing money rapidly due to leverage. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.
More guides on Finder
-
Best moisturiser for dry skin in Australia
From the best overall face moisturiser for dry skin to the best body moisturiser, hand moisturiser and tinted moisturiser for dry skin, these are the best 7 moisturisers for dry skin you can buy in Australia right now.
-
Best RC planes in Australia
From the best RC plane for beginners to the top model for aerial photography, these are the six best RC planes in Australia right now.
-
How to buy Pharmaxis units | A$51.65
Steps to owning and managing Vanguard Australian Fixed Interest Index ETF units.
-
How to buy Pharmaxis units | A$52.8
Steps to owning and managing Vanguard Ethically Conscious Global Aggregate Bond Index (Hedged) ETF units.
-
How to buy Pharmaxis units | A$104.04
Steps to owning and managing ETFS Morningstar Global Technology ETF units.
-
How to buy Pharmaxis units | A$24.04
Steps to owning and managing BetaShares Global Quality Leaders (Currency Hedged) ETF units.
-
How to buy Pharmaxis units | A$89.5
Steps to owning and managing ETFS ROBO Global Robotics and Automation ETF units.
-
How to buy Pharmaxis units | A$16.94
Steps to owning and managing ETFS FANG+ ETF units.
-
How to buy Pharmaxis units | A$73.79
Steps to owning and managing ETFS S&P Biotech ETF units.
-
How to buy Pharmaxis units | A$51.56
Steps to owning and managing ETFS Reliance India Nifty 50 ETF units.
Ask an Expert
